192 related articles for article (PubMed ID: 23411030)
1. Interaction of vanadium(IV) with human serum apo-transferrin.
Mehtab S; Gonçalves G; Roy S; Tomaz AI; Santos-Silva T; Santos MF; Romão MJ; Jakusch T; Kiss T; Pessoa JC
J Inorg Biochem; 2013 Apr; 121():187-95. PubMed ID: 23411030
[TBL] [Abstract][Full Text] [Related]
2. A novel V(IV)O-pyrimidinone complex: synthesis, solution speciation and human serum protein binding.
Gonçalves G; Tomaz I; Correia I; Veiros LF; Castro MM; Avecilla F; Palacio L; Maestro M; Kiss T; Jakusch T; Garcia MH; Pessoa JC
Dalton Trans; 2013 Sep; 42(33):11841-61. PubMed ID: 23677414
[TBL] [Abstract][Full Text] [Related]
3. Biospeciation of various antidiabetic V(IV)O compounds in serum.
Jakusch T; Hollender D; Enyedy EA; González CS; Montes-Bayón M; Sanz-Medel A; Costa Pessoa J; Tomaz I; Kiss T
Dalton Trans; 2009 Apr; (13):2428-37. PubMed ID: 19290378
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the binding of oxovanadium(IV) to human serum albumin.
Correia I; Jakusch T; Cobbinna E; Mehtab S; Tomaz I; Nagy NV; Rockenbauer A; Pessoa JC; Kiss T
Dalton Trans; 2012 Jun; 41(21):6477-87. PubMed ID: 22476413
[TBL] [Abstract][Full Text] [Related]
5. Behavior of the potential antitumor V(IV)O complexes formed by flavonoid ligands. 2. Characterization of sulfonate derivatives of quercetin and morin, interaction with the bioligands of the plasma and preliminary biotransformation studies.
Sanna D; Ugone V; Pisano L; Serra M; Micera G; Garribba E
J Inorg Biochem; 2015 Dec; 153():167-177. PubMed ID: 26281973
[TBL] [Abstract][Full Text] [Related]
6. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
Bordbar AK; Creagh AL; Mohammadi F; Haynes CA; Orvig C
J Inorg Biochem; 2009 Apr; 103(4):643-7. PubMed ID: 19056126
[TBL] [Abstract][Full Text] [Related]
7. New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
Liboiron BD; Thompson KH; Hanson GR; Lam E; Aebischer N; Orvig C
J Am Chem Soc; 2005 Apr; 127(14):5104-15. PubMed ID: 15810845
[TBL] [Abstract][Full Text] [Related]
8. A molecular docking study of the interactions between human transferrin and seven metallocene dichlorides.
Güette-Fernández JR; Meléndez E; Maldonado-Rojas W; Ortega-Zúñiga C; Olivero-Verbel J; Parés-Matos EI
J Mol Graph Model; 2017 Aug; 75():250-265. PubMed ID: 28609757
[TBL] [Abstract][Full Text] [Related]
9. Binding of vanadium to human serum transferrin - voltammetric and spectrometric studies.
Azevedo CG; Correia I; Dos Santos MMC; Santos MFA; Santos-Silva T; Doutch J; Fernandes L; Santos HM; Capelo JL; Pessoa JC
J Inorg Biochem; 2018 Mar; 180():211-221. PubMed ID: 29355752
[TBL] [Abstract][Full Text] [Related]
10. Speciation of potential anti-diabetic vanadium complexes in real serum samples.
Sanna D; Ugone V; Serra M; Garribba E
J Inorg Biochem; 2017 Aug; 173():52-65. PubMed ID: 28499214
[TBL] [Abstract][Full Text] [Related]
11. Interaction of insulin-enhancing vanadium compounds with human serum holo-transferrin.
Sanna D; Micera G; Garribba E
Inorg Chem; 2013 Oct; 52(20):11975-85. PubMed ID: 24090437
[TBL] [Abstract][Full Text] [Related]
12. New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.
Sanna D; Micera G; Garribba E
Inorg Chem; 2010 Jan; 49(1):174-87. PubMed ID: 19947643
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of V(IV)O complexes of picolinate and pyrazine derivatives. Behavior in the solid state and aqueous solution and biotransformation in the presence of blood plasma proteins.
Koleša-Dobravc T; Lodyga-Chruscinska E; Symonowicz M; Sanna D; Meden A; Perdih F; Garribba E
Inorg Chem; 2014 Aug; 53(15):7960-76. PubMed ID: 25013935
[TBL] [Abstract][Full Text] [Related]
14. Binding patterns of vanadium ions with different valence states to human serum transferrin studied by HPLC/high-resolution ICP-MS.
Nagaoka MH; Yamazaki T; Maitani T
Biochem Biophys Res Commun; 2002 Sep; 296(5):1207-14. PubMed ID: 12207902
[TBL] [Abstract][Full Text] [Related]
15. Competition between Al
Ott DB; Hartwig A; Stillman MJ
Metallomics; 2019 May; 11(5):968-981. PubMed ID: 30916671
[TBL] [Abstract][Full Text] [Related]
16. V
Sanna D; Ugone V; Sciortino G; Buglyó P; Bihari Z; Parajdi-Losonczi PL; Garribba E
Dalton Trans; 2018 Feb; 47(7):2164-2182. PubMed ID: 29327005
[TBL] [Abstract][Full Text] [Related]
17. Investigation on the interaction between tamoxifen and human holo-transferrin: determination of the binding mechanism by fluorescence quenching, resonance light scattering and circular dichroism methods.
Sarzehi S; Chamani J
Int J Biol Macromol; 2010 Nov; 47(4):558-69. PubMed ID: 20708639
[TBL] [Abstract][Full Text] [Related]
18. Interaction of antidiabetic vanadium compounds with hemoglobin and red blood cells and their distribution between plasma and erythrocytes.
Sanna D; Serra M; Micera G; Garribba E
Inorg Chem; 2014 Feb; 53(3):1449-64. PubMed ID: 24437949
[TBL] [Abstract][Full Text] [Related]
19. Binding patterns of vanadium to transferrin in healthy human serum studied with HPLC/high resolution ICP-MS.
Nagaoka MH; Akiyama H; Maitani T
Analyst; 2004 Jan; 129(1):51-4. PubMed ID: 14737583
[TBL] [Abstract][Full Text] [Related]
20. Direct thermodynamic and kinetic measurements of Fe²⁺ and Zn²⁺ binding to human serum transferrin.
Terpstra T; McNally J; Han TH; Ha-Duong NT; El-Hage-Chahine JM; Bou-Abdallah F
J Inorg Biochem; 2014 Jul; 136():24-32. PubMed ID: 24705244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
